Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Bauer, M. Articles by Müller-Oerlinghausen, B. Search for Related Content PubMed Citation Articles by Bauer, M. Articles by Müller-Oerlinghausen, B. Depression Antidepressants Lithium

Double-Blind, Placebo-Controlled Trial of the Use of Lithium to Augment Antidepressant Medication in Continuation Treatment of Unipolar Major Depression

OBJECTIVE: Use of lithium to augment antidepressant medication has been shown to be beneficial in the acute treatment of depression. The authors examined the efficacy of lithium augmentation in the continuation treatment of unipolar major depressive disorder. METHOD: Thirty patients with a refractory major depressive episode who had responded to acute lithium augmentation during an open 6-week study participated in a randomized, parallel-group, double-blind, placebo-controlled trial of lithium augmentation during continuation treatment. After a 2–4-week stabilization period following remission, patients were randomly assigned to receive either lithium or placebo for a 4-month period. Antidepressant medication was continued throughout the study. RESULTS: Relapses (including one suicide) occurred in seven (47%) of the 15 patients who received placebo in addition to antidepressants. None (0%) of the 14 patients who received lithium augmentation with antidepressants suffered a relapse during the double-blind phase of the study. Five of the seven relapsing patients in the placebo group developed a depressive episode, and the other two experienced a manic episode. CONCLUSIONS: Lithium augmentation in the continuation phase of treatment of unipolar major depressive disorder effectively protects patients against a relapse. Patients who respond to lithium augmentation should be maintained on lithium augmentation for a minimum of 6 months or even longer.

This article has been cited by other articles:

				A. A. Nierenberg, M. Fava, M. H. Trivedi, S. R. Wisniewski, M. E. Thase, P. J. McGrath, J. E. Alpert, D. Warden, J. F. Luther, G. Niederehe, et al. A Comparison of Lithium and T3 Augmentation Following Two Failed Medication Treatments for Depression: A STAR*D Report Am J Psychiatry, September 1, 2006; 163(9): 1519 - 1530. [Abstract] [Full Text] [PDF]

				A. A. Nierenberg, P. Eidelman, Y. Wu, and M. Joseph Depression: An Update for the Clinician Focus, January 1, 2005; 3(1): 3 - 12. [Full Text] [PDF]

				F. K. Goodwin, B. Fireman, G. E. Simon, E. M. Hunkeler, J. Lee, and D. Revicki Suicide Risk in Bipolar Disorder During Treatment With Lithium and Divalproex JAMA, September 17, 2003; 290(11): 1467 - 1473. [Abstract] [Full Text] [PDF]

				Other articles noted Evid. Based Ment. Health, August 1, 2001; 4(3): 72 - 72. [Full Text] [PDF]

Get information about faster international access.

Privacy Policy

Copyright © 2000 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us